Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17087008 | 0.84 | KDM1A (0.56) | ESR1KDM1A | |
| SCHEMBL21780738 | 0.81 | KDM1A (0.54) | ESR1KDM1A | |
| SCHEMBL17845178 | 0.81 | ESR1 (0.56) | ESR1 | |
| SCHEMBL20683542 | 0.81 | ESR1 (0.47) | ESR1 | |
| SCHEMBL25569792 | 0.81 | ESR1 (0.53) | ESR1 | |
| SCHEMBL17838456 | 0.81 | KDM4E (0.56) | ESR1KDM1A | |
| SCHEMBL21780731 | 0.79 | HRH3 (0.49) | ESR1 | |
| SCHEMBL23475063 | 0.78 | MEN1 (0.54) | ESR1 | |
| SCHEMBL16361996 | 0.78 | ESR1 (0.44) | ESR1 | |
| SCHEMBL23474910 | 0.78 | KDM4E (0.62) | ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112424205-A | Selective estrogen receptor degraders | 伊莱利利公司 | 2021-02-26 | — | — | CN | claimed |
| US-11993608-B2 | Selective estrogen receptor degraders | ELI LILLY AND COMPANY (US) | 2024-05-28 | — | — | US | disclosed |
| CN-117379428-A | Selective estrogen receptor degrading agent | 伊莱利利公司 | 2024-01-12 | — | — | CN | disclosed |
| CN-112424205-B | Selective estrogen receptor degrading agents | 伊莱利利公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116981679-A | Selective estrogen receptor degrading agent | 伊莱利利公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-112638916-B | Selective estrogen receptor degrading agent | 伊莱利利公司 | 2023-09-12 | — | — | CN | disclosed |
| US-11744844-B2 | Selective estrogen receptor degraders | ELI LILLY AND COMPANY (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230234960-A1 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS | ELI LILLY AND COMPANY | 2023-07-27 | — | — | US | disclosed |
| CN-112638916-A | Selective estrogen receptor degraders | 伊莱利利公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-112424205-A | Selective estrogen receptor degraders | 伊莱利利公司 | 2021-02-26 | — | — | CN | disclosed |
| CN-107406424-B | Estrogen receptor modulators and uses thereof | 豪夫迈·罗氏有限公司 | 2020-08-25 | — | — | CN | disclosed |
| US-10654866-B2 | Selective estrogen receptor degraders | ELI LILLY AND COMPANY (US) | 2020-05-19 | — | — | US | disclosed |
| EP-3233828-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016097071-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11744844-B2 | Selective estrogen receptor degraders | ESR1, ESR2, ESRRA | ESR1 1/4885KDM1A 457/4885 |
| US-20230234960-A1 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS | ESR1, GPER1, ESR2 | ESR1 1/4885KDM1A 650/4885 |
| US-11993608-B2 | Selective estrogen receptor degraders | ESR1, GPER1, ESR2 | ESR1 1/4885KDM1A 650/4885 |
| US-10654866-B2 | Selective estrogen receptor degraders | ESR1, GPER1, ESR2 | ESR1 1/4885KDM1A 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.